Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Cutera Reports Fourth Quarter and Full Year 2017 Record Revenue and Financial Results
By: Nasdaq / GlobeNewswire - 14 Feb 2018Back to overview list

Record Fourth Quarter Revenue of $47.6 Million; Increases 26% Year-over-Year; 14th Consecutive Quarter of Double-Digit Revenue Growth

System Revenue Grows in the Fourth Quarter by 35% in North America and 19% Internationally

Full Year Revenue Grows 28%

Company Expands Product Offerings in 2018 with Introduction of Juliet® and Secret RF®

BRISBANE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (NASDAQ:CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.

James Reinstein, President and Chief Executive Officer stated, “We are pleased with our fourth quarter and fiscal year 2017 performance. Our 26% global revenue growth in the fourth quarter was driven by the continued strength of systems revenue in North America, which increased 35%, as well as, considerable improvement in our International systems revenue, which increased 19%.  We believe the enhancements made to our International structure in 2017 will continue to drive execution improvements. We expect to build upon our 2017 success with continued North American and International expansion of legacy and newly launched products, as well as, consumables revenue related to truSculpt 3D®, Juliet and Secret RF.  In the second half 2017, approximately 30% of our systems sold will realize a recurring revenue stream going forward.  We believe our newly created Commercial Team dedicated to supporting our consumable products will help expand this revenue opportunity.” 

Key financial highlights for the fourth quarter 2017, when compared to the fourth quarter 2016, include:

  • Revenue increased 26% to a record $47.6 million, due primarily to an overall growth of 30% in systems revenue, with 35% growth in North America and 19% Internationally;
    • Record quarter of $11.5 million International systems revenue;
    • 25% sequential quarter increase compared to the third quarter of 2017;
    • Fourteenth consecutive quarter of double-digit year-over-year revenue growth;
  • Gross Margin of 57% impacted by increased warranty costs, as well as, an increased investment in our Service operations to fuel future growth;
  • Net Income was $22.9 million, or $1.57 per fully diluted share, including a benefit for the release of a significant portion of our valuation allowance against U.S. deferred tax assets;
    • Non-GAAP net income* was $6.1 million, or $0.42 per fully diluted share.  In the fourth quarter of 2017, the Company recorded an income tax benefit of $18.2 million resulting primarily from the release of a significant portion of its valuation allowance against certain U.S. deferred tax assets, partially offset by the revised measurement of U.S. deferred tax assets resulting from the Tax Cuts and Jobs Act of 2017;
  • Cash Generated by Operations increased 41% to $6.7 million, compared to $4.7 million in the prior period;
  • Cash, cash equivalents and investments of $35.9 million, with no debt; and
  • Repurchased $21.4 million of common stock.

Key financial highlights for the full year 2017, when compared to the full year 2016, were as follows:

  • Revenue increased 28% for the full year to a record $151.5 million, due primarily to a 51% growth in North American systems revenue;
    • Three consecutive years of 20%+ year-over-year growth;
  • Gross Margin of 57% was slightly lower than previous year, impacted by warranty costs and an increased investment in our Service operations in the second half of 2017;
  • Net Income was $30.0 million, or $2.04 per fully diluted share;
    • Non-GAAP net income* was $13.7 million, or $0.93 per fully diluted share;
  • Cash Generated by Operations was $14.3 million, including the one-time $4 million benefit from our facility lease cancellation in the third quarter of 2017; and
  • Repurchased $35.2 million of common stock.

Product Updates

Each platform in our portfolio contributed to the success of the year.  The Company’s newly launched truSculpt 3D system continues to gain market acceptance in North America and in International markets.  In 2018, the Company expects continued North American growth for the truSculpt platform, as well as, expansion into new International markets. Additionally, the Enlighten family continues to be a top selling platform and closely follows truSculpt 3D in total revenue.  In January 2018, the Company launched Juliet (a women’s health product) and Secret RF (an RF microneedle product) to further enhance our product offerings, as well as expand our participation in recurring procedural revenue.  As previously announced, Cutera also created a commercial organization dedicated to supporting consumable products for procedures performed in physicians’ practices.  We expect this new team, combined with the new consumable offerings, to expand disposable revenue opportunities in 2018 and beyond.

2018 Outlook

  • We expect revenue to be in the range of $178 to $181 million, an 18% - 20% increase over 2017;
  • Gross margin is expected to be in the range of 57% to 58%, as we continue to invest in our Service operations, and experience increased facility costs in our headquarters in Brisbane, California;
  • Operating expenses are expected to be in the range of 52% to 54% of revenue, consistent with 2017 (excluding the non-recurring lease termination benefit), as we continue to invest in product development and the scalability of our operations;
  • Non-GAAP earnings per share* is expected to be in the range of $1.03 to $1.11 as compared to $0.93 for the full-year of 2017; and
  • Adjusted EBITDA* is expected to be in the range of $15.0 to $17.0 million.

Conference Call

The conference call to discuss these results is scheduled to begin today at 1:30 p.m. PST (4:30 p.m. EST).  Participating in the call will be James Reinstein, President and Chief Executive Officer and Sandra Gardiner, Executive Vice President and Chief Financial Officer.  The call will be broadcast live over the Internet, hosted at the Investor Relations section of Cutera's website at http://www.cutera.com/, and will be archived online within one hour of its completion through February 28, 2018. In addition, you may call 1-877-705-6003 to listen to the live broadcast.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has developed innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

Use of Non-GAAP Financial Measures

* In order to supplement our unaudited condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management discloses certain non-GAAP financial measures. Management uses these measures as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for benchmarking against other medical technology companies.  Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.  These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP.

We have provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.  We have not provided a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability, limited visibility, unpredictability, or unique non-recurring nature of the excluded items.  Forward-looking non-GAAP measures include adjusted earnings per share and adjusted EBITDA.  We define adjusted EBITDA as earnings before interest, taxes, depreciation and amortization as adjusted for non-cash stock-based compensation expense.  For computing non-GAAP earnings per share and adjusted EBITDA, we have assumed $8 to $9 million of non-cash stock-based compensation, an effective tax rate of 10% to 12%, and approximately 15 million weighted-average shares outstanding.

In this press release management has disclosed certain non-GAAP financial measures for the statement of operations and net income per diluted share, which exclude the following:

Non-cash expenses for stock-based compensation. We have excluded the effect of stock-based compensation expenses in calculating our non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to our employees, we continue to evaluate our business performance excluding stock-based compensation expenses. We record non-cash compensation expense related to grants of options, performance and restricted stock. Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods.  We believe that excluding this item allows users of our financial statements to better review and assess both current, and historical results of operations.  We also believe that excluding non-cash expenses for stock-based compensation better allows for comparisons to our peer companies.

Depreciation. We have excluded depreciation expense in calculating our non-GAAP operating expenses and net income measures.  Depreciation is a non-cash charge to current operations.  We continue to evaluate our business performance excluding non-cash charges and believe that excluding this item allows users of our financial statements to better review and assess both current, and historical results of operations.

Non-recurring lease termination income.  We incurred a one-time benefit with respect to a certain lease termination transaction.  We exclude this benefit as it is related to a unique, one-time event and has no direct impact or correlation to the operation of our on-going business. Additionally, we believe that its inclusion is potentially misleading to users of our financial statements given the lease termination income’s unique, non-recurring nature.

Non-recurring income tax adjustments relating primarily to the release of a significant portion of the Company’s valuation allowance against certain U.S. deferred tax assets, partially offset by the impact of the Tax Cuts and Jobs Act of 2017.  We exclude this adjustment as it is related to a unique, non-recurring event and has no direct impact or correlation to the operation of our on-going business.  Additionally, we believe that its inclusion is potentially misleading to users of our financial statements given its unique, non-recurring nature.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management. 

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, Cutera’s plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All information in this press release is as of the date of its release.  Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Cutera's financial performance for the fourth quarter ended December 31, 2017, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

   
 CUTERA, INC.  
 CONDENSED CONSOLIDATED BALANCE SHEETS 
 (in thousands)  
 (unaudited)  
   
       December 31,  September 30,  December 31, 
       2017  2017  2016 
 Assets           
 Current assets:          
 Cash and cash equivalents $14,184 $14,784 $13,775 
 Marketable investments  21,728  35,692  40,299 
 Cash, cash equivalents and investments  35,912  50,476  54,074 
               
 Accounts receivable, net  20,777  19,604  16,547 
 Inventories  28,782  23,728  14,977 
 Other current assets and prepaid expenses  2,903  2,894  2,251 
 Total current assets  88,374  96,702  87,849 
               
 Property and equipment, net  2,096  1,842  1,907 
 Deferred tax asset  19,055  384  377 
 Intangibles, net      2 
 Goodwill  1,339  1,339  1,339 
 Other long-term assets  374  381  380 
 Total assets $111,238 $100,648 $91,854 
               
 Liabilities and Stockholders' Equity          
 Current liabilities:          
 Accounts payable $7,002 $5,805 $2,598 
 Accrued liabilities  26,848  22,203  17,397 
 Deferred revenue  9,461  8,801  8,394 
 Total current liabilities  43,311  36,809  28,389 
               
 Deferred revenue, net of current portion  2,195  1,950  1,705 
 Income tax liability  379  171  168 
 Other long-term liabilities  460  505  582 
 Total liabilities  46,345  39,435  30,844 
               
 Stockholders' equity  64,893  61,213  61,010 
 Total liabilities and stockholders' equity $111,238 $100,648 $91,854 
               

 

   
 CUTERA, INC.  
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
 (in thousands, except per share data) 
 (unaudited)  
       
     Three Months Ended Twelve Months Ended 
     December 31, December 31, December 31, December 31, 
     2017
 2016
 2017
 2016
 
 Net revenue $47,632  $37,875  $151,493  $118,056  
 Cost of revenue  20,299   15,962   65,383   49,921  
 Gross profit  27,333   21,913   86,110   68,135  
 Gross margin %  57%  58%  57%  58% 
                 
 Operating expenses:             
 Sales and marketing  15,362   11,561   52,070   41,563  
 Research and development  3,481   2,897   12,874   11,232  
 General and administrative  3,947   3,010   14,090   12,943  
 Lease termination        (4,000)    
 Total operating expenses  22,790   17,468   75,034   65,738  
 Income from operations  4,543
Related companies:Cutera
Copyright 2018 Nasdaq / GlobeNewswire Back to overview list
to the top ↑